<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Chimeric Antigen Receptor Therapy for B-cell Malignancies

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2011Publisher:Ivyspring International PublisherJournal:Journal of Cancer, volume 2, pages 331-332 (issn: 1837-9664,

Authors: David L. Porter; Bruce L. Levine; Carl H. June; Michael Kalos; Zhaohui Zheng;

doi: 10.7150/jca.2.331

pmid: 21716851

pmc: PMC3119397

Chimeric Antigen Receptor Therapy for B-cell Malignancies

- Summary
- Metrics

Abstract

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Related Organizations

University of Pennsylvania
United States
Abramson Cancer Center
United States
University Medical Center
United States

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	83
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%